ORAMED PHARMACEUTICALS INC

ORMPNASDAQ

🏆 #3219 by market capEarnings Nov 12US Equity

$4.25▲ $0.05 (+1.19%)

🌅 Pre-market$4.32▲ 1.65%Regular close · extended-hours price shown

1h—

24h▲ 1.2%

7d▼ 1.8%

14d▲ 7.1%

30d▲ 7.6%

1y▲ 103.3%

🏦Market Cap

$174M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $4.20 – $4.29
52-Week Range: $1.98 – $5.19
Volume: $2.04B
Avg Volume: $1.81B
Shares Outstanding: 40.9M
Next Earnings: Oct 2, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $515,103
P/E Ratio: 1.0
P/S Ratio: 0.0x
EPS (TTM): $4.83
Dividend Yield: 5.88%

Why Investors Own ORMP

✓High-growth profile — revenue up +9.9% YoY with expanding US Equity exposure.
✓Healthy economics — 79% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +5.9% YoY

Gross Margin (TTM)

79.2%▲ +1.3% YoY

Operating Income (TTM)

$624,000▲ +5.9% YoY

Free Cash Flow (TTM)

$556,000▲ +5.9% YoY

About ORAMED PHARMACEUTICALS INC

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

🦦